ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2100

Hypomethylation in Enhancer and Promoter Regions of Interferon Regulated Genes in Multiple Tissues Is Associated with Primary Sjögren’s Syndrome

Juliana Imgenberg-Kreuz1, Johanna K Sandling1,2, Jonas Carlsson Almlöf1, Jessica Nordlund1, Linnea Signér2, Katrine B Norheim3, Roald Omdal3, Majia-Leena Eloranta2, Lars Rönnblom2, Ann-Christine Syvänen1 and Gunnel Nordmark2, 1Molecular Medicine and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 2Rheumatology and Science for Life Laboratory, Department of Medical Sciences, Uppsala University, Uppsala, Sweden, 3Clinical Immunology Unit, Department of Internal Medicine, Stavanger University Hospital, Stavanger, Norway

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: autoimmune diseases and epigenetics, DNA Methylation, Gene Expression, Sjogren's syndrome

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Genetics, Genomics and Proteomics

Session Type: ACR Concurrent Abstract Session

Session Time: 4:30PM-6:00PM

Background/Purpose:

Epigenetic modifications have emerged as important contributing factors in the pathogenesis of autoimmune diseases, including primary Sjögren’s syndrome (pSS), and may act as a link between the environment and the genome. The aim of this study was to investigate DNA methylation in multiple tissues and its functional implications for pSS susceptibility.

Methods:

DNA prepared from whole blood samples (patients n=100, controls n=400), positively selected CD19+ B cells (patients n=24, controls n=47) and minor salivary gland biopsies (patients n=15, controls n=13) was analysed on the Illumina HumanMethylation 450k array, covering 485,000 CpG sites across the genome.  Age and sex were included as covariates in the association model and a p-value of <1×10-7 was considered significant (Bonferroni correction). Genomic coordinates of differentially methylated sites were tested for overlap with histone marks in publicly available data from reference B and T cells, and the association of genetic variants in known pSS risk loci with DNA methylation was investigated. In addition, gene expression was analysed by RNA-sequencing in CD19+ B cells from 16 patients and 24 controls.

Results:

We identified prominent hypomethylation in type I interferon regulated genes in whole blood, CD19+ B cells and minor salivary gland biopsies in patients with pSS. Enrichment for genomic overlap of these differentially methylated sites with histone marks of enhancer and promoter regions was observed. Analysis in whole blood from the controls showed that genetic variants located in or close to the pSS risk loci DDX6-CXCR5, FAM167A-BLK, IL12A, IRF5-TNPO3, STAT4, TNIP1, and within the HLA-region were associated with methylation levels at proximal CpG sites. In CD19+ B cells a correlation between hypomethylation and increased gene expression levels was identified for several interferon regulated genes with prominent hypomethylated sites overlapping enhancer regions, these genes included MX1, IFI44L, IFITM1 and RSAD2.

Conclusion:

Our results further emphasize the role of DNA methylation in the pathogenesis of pSS. The importance of genes in the interferon system is highlighted, and the correlation with altered gene expression suggests a potential functional mechanism for differentially methylated CpG sites in pSS.


Disclosure: J. Imgenberg-Kreuz, None; J. K. Sandling, None; J. Carlsson Almlöf, None; J. Nordlund, None; L. Signér, None; K. B. Norheim, None; R. Omdal, None; M. L. Eloranta, None; L. Rönnblom, None; A. C. Syvänen, None; G. Nordmark, None.

To cite this abstract in AMA style:

Imgenberg-Kreuz J, Sandling JK, Carlsson Almlöf J, Nordlund J, Signér L, Norheim KB, Omdal R, Eloranta ML, Rönnblom L, Syvänen AC, Nordmark G. Hypomethylation in Enhancer and Promoter Regions of Interferon Regulated Genes in Multiple Tissues Is Associated with Primary Sjögren’s Syndrome [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/hypomethylation-in-enhancer-and-promoter-regions-of-interferon-regulated-genes-in-multiple-tissues-is-associated-with-primary-sjogrens-syndrome/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/hypomethylation-in-enhancer-and-promoter-regions-of-interferon-regulated-genes-in-multiple-tissues-is-associated-with-primary-sjogrens-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology